Aprea Therapeutics, Inc. APRE made its public debut Thursday morning, opening at $15.46 after being priced at $15 per share.
The shares are listed on the Nasdaq under the ticker symbol “APRE.”
Aprea Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53.
JPMorgan, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.
Related Links:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
